Five-Year Allograft Survival for Recipients of Kidney Transplants From Hepatitis C Virus Infected vs Uninfected Deceased Donors in the Direct-Acting Antiviral Therapy Era.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 35994263.
- Also identified by DOI 10.1001/jama.2022.12868 and PMC identifier 9396466.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This cohort study examines the validity of the Kidney Donor Profile Index’s hepatitis C virus (HCV) penalty during the direct-acting antiviral era by comparing 5-year allograft survival between recipients of kidneys from HCV-RNA–positive donors vs HCV-RNA–negative donors.
Medical subject headings
- Allografts
- Antiviral Agents
- Graft Survival
- Hepatitis C
- Kidney Failure, Chronic
- Kidney Transplantation